Bailard Inc. Has $847,000 Position in AbbVie Inc (ABBV)

Bailard Inc. increased its position in shares of AbbVie Inc (NYSE:ABBV) by 15.2% during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,191 shares of the company’s stock after acquiring an additional 1,213 shares during the quarter. Bailard Inc.’s holdings in AbbVie were worth $847,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds have also recently made changes to their positions in ABBV. Wade G W & Inc. increased its stake in AbbVie by 11.8% during the fourth quarter. Wade G W & Inc. now owns 14,072 shares of the company’s stock worth $1,297,000 after purchasing an additional 1,486 shares during the period. Integrated Investment Consultants LLC increased its stake in AbbVie by 1.0% during the fourth quarter. Integrated Investment Consultants LLC now owns 12,662 shares of the company’s stock worth $1,168,000 after purchasing an additional 131 shares during the period. Certified Advisory Corp increased its stake in AbbVie by 5.8% during the fourth quarter. Certified Advisory Corp now owns 5,358 shares of the company’s stock worth $494,000 after purchasing an additional 294 shares during the period. Mutual of Omaha Bank Wealth Management increased its stake in AbbVie by 1.4% during the fourth quarter. Mutual of Omaha Bank Wealth Management now owns 127,333 shares of the company’s stock worth $11,739,000 after purchasing an additional 1,815 shares during the period. Finally, Roman Butler Fullerton & Co. purchased a new stake in AbbVie during the fourth quarter worth about $288,000. 70.66% of the stock is currently owned by hedge funds and other institutional investors.

A number of research firms recently weighed in on ABBV. Zacks Investment Research upgraded shares of AbbVie from a “hold” rating to a “buy” rating and set a $100.00 target price on the stock in a research note on Tuesday, January 8th. ValuEngine upgraded shares of AbbVie from a “strong sell” rating to a “sell” rating in a research note on Friday, March 15th. Barclays reiterated a “hold” rating and issued a $86.00 price target on shares of AbbVie in a research note on Thursday, February 14th. Credit Suisse Group raised AbbVie to a “hold” rating and set a $79.00 price objective for the company in a report on Thursday, January 17th. Finally, Morgan Stanley set a $88.00 price objective on AbbVie and gave the company a “hold” rating in a report on Thursday, December 20th. Six research analysts have rated the stock with a sell rating, eight have given a hold rating and five have issued a buy rating to the company’s stock. AbbVie currently has a consensus rating of “Hold” and an average price target of $94.48.

In other AbbVie news, Vice Chairman Laura J. Schumacher sold 25,000 shares of the firm’s stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $80.00, for a total value of $2,000,000.00. Following the sale, the insider now directly owns 139,838 shares of the company’s stock, valued at approximately $11,187,040. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, VP Brian L. Durkin sold 475 shares of the firm’s stock in a transaction dated Monday, March 25th. The stock was sold at an average price of $79.69, for a total value of $37,852.75. Following the completion of the sale, the vice president now directly owns 9,121 shares in the company, valued at $726,852.49. The disclosure for this sale can be found here. In the last quarter, insiders have sold 41,272 shares of company stock valued at $3,286,290. 0.08% of the stock is currently owned by company insiders.

NYSE:ABBV traded up $0.25 during trading hours on Monday, hitting $81.03. The company’s stock had a trading volume of 3,293,206 shares, compared to its average volume of 6,559,839. The stock has a market capitalization of $119.16 billion, a price-to-earnings ratio of 10.24, a PEG ratio of 1.68 and a beta of 1.16. AbbVie Inc has a 52-week low of $75.77 and a 52-week high of $107.25.

AbbVie (NYSE:ABBV) last released its quarterly earnings data on Friday, January 25th. The company reported $1.90 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $1.92 by ($0.02). AbbVie had a negative return on equity of 439.07% and a net margin of 17.36%. The business had revenue of $8.31 billion during the quarter, compared to analysts’ expectations of $8.37 billion. During the same quarter in the previous year, the company posted $1.48 EPS. The company’s revenue was up 7.3% compared to the same quarter last year. Sell-side analysts anticipate that AbbVie Inc will post 8.69 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, May 15th. Investors of record on Monday, April 15th will be given a dividend of $1.07 per share. This represents a $4.28 dividend on an annualized basis and a yield of 5.28%. The ex-dividend date of this dividend is Friday, April 12th. AbbVie’s dividend payout ratio is presently 54.11%.

TRADEMARK VIOLATION WARNING: “Bailard Inc. Has $847,000 Position in AbbVie Inc (ABBV)” was originally posted by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this report on another site, it was illegally stolen and republished in violation of United States & international trademark & copyright law. The legal version of this report can be read at https://www.baseballdailydigest.com/news/2019/04/16/abbvie-inc-abbv-stake-increased-by-bailard-inc.html.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceutical products in the United States, Japan, Germany, Canada, Italy, Spain, the Netherlands, the United Kingdom, Brazil, and internationally. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma, waldenström's macroglobulinemia, marginal zone lymphoma, and chronic graft versus host disease; VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; VIEKIRA PAK, an interferon-free therapy to treat adults with genotype 1 chronic hepatitis C virus (HCV); TECHNIVIE to treat adults with genotype 4 HCV infection; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection.

Featured Story: Fundamental Analysis – How It Helps Investors

Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Receive News & Ratings for AbbVie Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AbbVie and related companies with MarketBeat.com's FREE daily email newsletter.